NCT06226727

A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1019" and Co-administration of "BR1019-1" and "BR1019-2"

A Randomized, Open-label, Single Dose, Two-way Replicate Crossover Phase 1 Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1019" and Co-administration of "BR1019-1" and "BR1019-2" in Healthy Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 52 (actual)
• Sponsor: Boryung Pharmaceutical Co., Ltd · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Accepted

Summary

The objective of this clinical study is to evaluate the pharmacokinetics and the safety after administration of "BR1019" and co-administration of "BR1019-1" and "BR1019-2" in healthy volunteers

Conditions

• Type 2 Diabetes Mellitus
• Essential Hypertension

Interventions

Type	Name	Description
DRUG	BR1019	One tablet administered alone
DRUG	BR1019-1	One tablet administered alone
DRUG	BR1019-2	One tablet administered alone

Timeline

• Start date: 2024-02-14
• Primary completion: 2024-03-31
• Completion: 2024-03-31
• First posted: 2024-01-26
• Last updated: 2024-04-02

Locations

1 site across 1 country: South Korea